- MarketWatch•2 hours ago
EyeGate Pharmaceuticals Inc. shares surged as much as 15% in pre-market trade Tuesday after an announcement of the company's licensing agreement with Valeant Pharmaceuticals International Inc. . The deal ...
- PR Newswire•3 hours agoValeant Pharmaceuticals And EyeGate Enter Into Licensing Agreement For EGP-437 Combination Product In Post-Operative Pain And Inflammation In Ocular Surgery Patients
LAVAL, Quebec and WALTHAM, Mass., Feb. 21, 2017 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) ("Valeant") and EyeGate Pharmaceuticals, Inc. (EYEG) ("EyeGate"), a specialty pharmaceutical company that focuses on developing and commercializing products for treating diseases and disorders of the eye, today announced that they have entered into an exclusive, worldwide licensing agreement through which EyeGate has granted a subsidiary of Valeant exclusive, worldwide commercial and manufacturing rights to the EyeGate® II Delivery System and EGP-437 combination product candidate for the treatment of post-operative pain and inflammation in ocular surgery patients. This partnership follows a 2015 agreement in which Valeant secured an exclusive worldwide license for its subsidiary to this product for uveitis.
- GuruFocus.com•18 hours ago
Francis Chou likes Valeant and continues to increase his position
VRX.TO : Summary for VALEANT PHARMACEUTICALS INTL IN - Yahoo Finance
Valeant Pharmaceuticals International, Inc. (VRX.TO)
Toronto - Toronto Delayed Price. Currency in CAD
Add to watchlist
|Day's Range||21.34 - 21.66|
|52 Week Range||17.19 - 117.03|
|PE Ratio (TTM)||-3.27|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|